drugset / Trial / NCT00097331
Three Months Treatment With SB683699 In Patients With Relapsing Multiple Sclerosis
RandomizedParallel-groupDouble-blindTreatment
Summary
The study will evaluate the effectiveness and safety of the investigational drug SB683699 in treating patients with relapsing multiple sclerosis (MS), using data from magnetic resonance imaging (MRI) scans as the main measure.
Timeline
- Start
- 2004-09
- Primary completion
- 2006-07
- Completion
- 2006-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Firategrast | Small molecule | 150 mg | — |
| Subject | Firategrast | Small molecule | 1200 mg | — |